Parcourir par auteur "Voliotis, G."
Voici les éléments 1-4 de 4
-
Endothelin-1 plasma levels in hemodialysis treatment - The influence of type 2 diabetes
Liakopoulos, V.; Wurth, P.; Mertens, P. R.; Eleftheriadis, T.; Kourti, P.; Voliotis, G.; Heintz, B.; Koukoulis, G. N.; Stefanidis, I. (2005)In patients on chronic hemodialysis the prevalence of atherosclerosis is increased and is by far the leading cause of morbidity and mortality. Endothelin-1, an endothelium-derived peptide with vasoconstrictive and mitogenic ... -
Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease
Liakopoulos, V.; Eleftheriadis, T.; Kyropoulos, T.; Voliotis, G.; Potamianos, S.; Zengos, N.; Stefanidis, I.; Heintz, B. (2005)Atherosclerosis is by far the leading cause of mortality and morbidity in patients with end stage renal disease undergoing chronic hemodialysis (HD). Vascular endothelial cell adhesion molecules like the intercellular ... -
Telomere length and telomerase activity in haemodialysis (HD) patients
Voliotis, G.; Tsezou, A.; Liakopoulos, V.; Giannopoulou, M.; Dovas, S.; Kourti, G.; Zintzaras, E.; Stefanidis, I. (2007) -
Telomere Length in Peripheral Blood Mononuclear Cells of Patients on Chronic Hemodialysis Is Related With Telomerase Activity and Treatment Duration
Stefanidis, I.; Voliotis, G.; Papanikolaou, V.; Chronopoulou, I.; Eleftheriadis, T.; Kowald, A.; Zintzaras, E.; Tsezou, A. (2015)Telomere shortening to a critical limit is associated with replicative senescence. This process is prevented by the enzyme telomerase. Oxidative stress and chronic inflammation are factors accelerating telomere loss. Chronic ...